Category: ACT-AD (Accelerate Cure/Treatments for Alzheimer’s Disease)

BrightFocus President and CEO Stacy Pagos Haller In honor of National Alzheimer’s Disease Awareness Month, the Alliance for Aging Research…

In October, the Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) coalition, which is chaired by the Alliance for Aging Research, attended the …

The majority of clinical trials conducted in Alzheimer’s disease have been for patients who received a definitive diagnosis after becoming…

Last month, the Alzheimer’s Association International Conference was held in London, England. While we are still years away from discovering a cure, the conference highlights the steady efforts of researchers and scientists to better understand the devastating disease.

On Tuesday, July 25, the Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) Coalition will hold a one-hour webinar on Alzheimer's disease research framework, featuring expert perspectives.

Researchers at the Keck School of Medicine of the University of Southern California may have discovered Alzheimer's disease in its earliest stage. Their findings provide greater insight into the disease and could offer new ways to treat the devastating disease.

On March 15, the Accelerate Cure/Treatments for Alzheimer's Disease (ACT-AD) Coalition hosted a webinar on symptomatic relief for Alzheimer's disease. An archived video of the webinar is now available. 

On Wednesday, March 15, at 12 p.m. EST, the Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) Coalition will hold a one-hour webinar on symptomatic relief for Alzheimer’s disease, featuring expert presentations.

On November 16, the ACT-AD (Accelerate Cure/Treatments for Alzheimer’s Disease) Coalition hosted its Ninth Annual FDA/Alzheimer’s Disease Allies Meeting in North Bethesda, Md., to discuss the current state of Alzheimer’s disease treatment development.

Today, senior representatives from the U.S. Food and Drug Administration (FDA) and the National Institute on Aging at the National Institutes of Health (NIH) joined with advocates, federal colleagues, researchers, and industry to explore collaborations for advancing the most up-to-date knowledge in Alzheimer’s disease research.